title: Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
abstract: OBJECTIVE
  To evaluate the short-term visual acuity and anatomic responses after intravitreal bevacizumab (Avastin, Genentech) treatment in patients with retinal angiomatous proliferation (RAP).
  
  
  METHODS
  The authors conducted a retrospective review of consecutive patients with newly diagnosed or recurrent RAP treated with intravitreal bevacizumab (1.25 mg) during a 3-month period. Complete ocular examination was performed at baseline and follow-up visits. Interval data were analyzed statistically at 1 and 3 months follow-up.
  
  
  RESULTS
  Twenty-three eyes of 23 patients underwent intravitreal bevacizumab treatment. The mean age of patients was 81.1 years, median baseline visual acuity of treated eyes was 20/80 (range 20/25-20/800), and mean baseline central macular thickness was 335 mum (optical coherence tomography was available for 22 eyes). Nine eyes had retinal pigment epithelial detachments (PEDs) at baseline. At 1-month follow-up, the median acuity improved to 20/60 (range 20/30-20/400) (P < 0.001), mean central macular thickness decreased to 202 microm (P < 0.001), and PED was present in only 2 eyes (P = 0.016). Seven of 23 eyes at 1 month (30.4%) had improved visual acuity, defined as halving of the visual angle, and no eyes had worse acuity, defined as doubling of the visual angle. Of the 17 eyes available for 3-month follow-up, 5 eyes (29.4%) had better visual acuity, 1 eye (5.9%) had worse acuity, and the remaining 11 (64.7%) had the same acuity. The median visual acuity at month 3 was 20/60 (range 20/25-20/400). There were no thromboembolic phenomena, endophthalmitis cases, retinal detachments, or any other adverse events.
  
  
  CONCLUSIONS
  Treatment of RAP with intravitreal bevacizumab during this retrospective review resulted in a significant decrease in macular thickness and improvement or stabilization of visual acuity. Further long-term investigation is warranted given the promising short-term results.
authors.affiliation: LuEsther T. Mertz Retinal Research Center/Manhattan Eye, Ear & Throat Hospital and Vitreous-Retina-Macula Consultants of New York, New York, USA.
authors.forename: Catherine B
authors.initials: CB
authors.lastname: Meyerle
authors.forename: K Bailey
authors.initials: KB
authors.lastname: Freund
authors.forename: Diana
authors.initials: D
authors.lastname: Iturralde
authors.forename: Richard F
authors.initials: RF
authors.lastname: Spaide
authors.forename: John A
authors.initials: JA
authors.lastname: Sorenson
authors.forename: Jason S
authors.initials: JS
authors.lastname: Slakter
authors.forename: James M
authors.initials: JM
authors.lastname: Klancnik
authors.forename: Yale L
authors.initials: YL
authors.lastname: Fisher
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Cooney
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Yannuzzi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000798:Angiomatosis / Q000175:diagnosis / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab